Skip to main content
. 2019 Feb 21;4(1):123–132. doi: 10.1002/epi4.12304

Table 3.

Incidence of adverse events (AEs) reported at T1

AEs occurring in >2.5% of all patients
AEs, n (%) Discontinued treatment (n = 82) Continued treatment (n = 78) All patients (n = 160)
No AEs 71 (86.5) 58 (74.3) 129 (80.6)
General weakness/fatigue 3 (3.6) 10 (12.8) 13 (8.1)
Somnolence 1 (1.2) 7 (8.9) 8 (5.0)
Weight gain 2 (2.4) 3 (3.8) 5 (3.1)
Hypersalivation 4 (5.1) 4 (2.5)
Dizziness 3 (3.6) 1 (1.2) 4 (2.5)

Data are n (%).